EDITAS MEDICINE INC (EDIT:NASDAQ)
$2.9 0.06 (2.1127%)
Analysed EDITAS MEDICINE INC (EDIT:NASDAQ) News Sources
Is Vertex Stock Worth More Than Its Competitors?
09-10-2026
trefis.com
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
05-08-2026
yahoo.com
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
05-08-2026
yahoo.com
Editas Medicine to Participate in Upcoming Investor Conferences
01-09-2026
yahoo.com
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
04-09-2026
yahoo.com
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
08-09-2026
yahoo.com
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
09-09-2026
yahoo.com
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
12-09-2026
marketbeat.com
Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
08-10-2026
stocktwits.com
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
09-10-2026
yahoo.com
What is the current price of EDITAS MEDICINE INC (EDIT:NASDAQ)?
The current price of EDITAS MEDICINE INC (EDIT:NASDAQ) is $2.9.
EDITAS MEDICINE INC (EDIT:NASDAQ) absolute price change since previous trading day?
The absolute price change of EDITAS MEDICINE INC (EDIT:NASDAQ) since the previous trading day is $0.06.
EDITAS MEDICINE INC (EDIT:NASDAQ) percentage price change since previous trading day?
The percentage price change of EDITAS MEDICINE INC (EDIT:NASDAQ) since the previous trading day is 2.1127%.
What is the most recent average sentiment score for EDITAS MEDICINE INC (EDIT:NASDAQ)?
The most recent average sentiment score for EDITAS MEDICINE INC (EDIT:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for EDITAS MEDICINE INC (EDIT:NASDAQ)?
The most recent sentiment for EDITAS MEDICINE INC (EDIT:NASDAQ) is .
SEC-8K** Filing Available For EDITAS MEDICINE INC (EDIT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.